Arrowhead Pharmaceuticals’ (ARWR) Outperform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reiterated their outperform rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a report issued on Friday morning,Benzinga reports. Royal Bank Of Canada currently has a $100.00 target price on the biotechnology company’s stock.

ARWR has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 17th. B. Riley Financial increased their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. increased their price target on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, July 17th. The Goldman Sachs Group assumed coverage on Arrowhead Pharmaceuticals in a research note on Thursday, September 24th. They issued a “neutral” rating and a $74.00 price target on the stock. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $98.93.

Check Out Our Latest Stock Report on ARWR

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $47.78 on Friday. The company has a quick ratio of 4.11, a current ratio of 4.14 and a debt-to-equity ratio of 16.61. The firm has a 50 day moving average price of $63.32 and a 200-day moving average price of $71.00. Arrowhead Pharmaceuticals has a twelve month low of $37.06 and a twelve month high of $95.49. The stock has a market capitalization of $6.73 billion, a price-to-earnings ratio of -9.35 and a beta of 1.34.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 11,600 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the sale, the director directly owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the transaction, the director owned 31,600 shares in the company, valued at $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. EP Wealth Advisors LLC increased its stake in shares of Arrowhead Pharmaceuticals by 0.9% in the 3rd quarter. EP Wealth Advisors LLC now owns 38,471 shares of the biotechnology company’s stock worth $2,518,000 after purchasing an additional 336 shares in the last quarter. Pathstone Holdings LLC raised its holdings in Arrowhead Pharmaceuticals by 2.5% in the 3rd quarter. Pathstone Holdings LLC now owns 18,252 shares of the biotechnology company’s stock worth $1,195,000 after purchasing an additional 451 shares during the period. Marshall Wace LLP lifted its position in Arrowhead Pharmaceuticals by 0.5% during the third quarter. Marshall Wace LLP now owns 306,491 shares of the biotechnology company’s stock valued at $20,060,000 after purchasing an additional 1,460 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in Arrowhead Pharmaceuticals by 0.6% during the third quarter. State Board of Administration of Florida Retirement System now owns 104,917 shares of the biotechnology company’s stock valued at $6,867,000 after purchasing an additional 595 shares in the last quarter. Finally, Evolutionary Tree Capital Management LLC lifted its position in Arrowhead Pharmaceuticals by 33.2% during the third quarter. Evolutionary Tree Capital Management LLC now owns 19,142 shares of the biotechnology company’s stock valued at $1,253,000 after purchasing an additional 4,774 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Key Headlines Impacting Arrowhead Pharmaceuticals

These are some of the ARWR headlines that stood out recently:

  • Positive Sentiment: Royal Bank of Canada reaffirmed its “outperform” rating and $100 price target, signaling continued analyst confidence in Arrowhead’s potential. Royal Bank of Canada rating
  • Neutral Sentiment: Stifel Nicolaus kept its “buy” rating but lowered its price target to $96 from $104, reflecting a more cautious valuation while retaining a bullish view. Stifel Nicolaus rating
  • Negative Sentiment: Arrowhead reported a full-year fiscal 2026 loss of $5.11 per share. An earnings analysis also highlights the challenge of making costly R&D pay off as market sentiment toward RNA interference (RNAi) turns more skeptical. Full-year earnings results Earnings analysis

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

Featured Stories

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.